FuXion Biotech

CEBINA | July 13, 2020

CEBINA GmbH, an Austrian biotech company, announces positive results of its COVID-19 drug repurposing project with the identification of commonly used approved drugs with activity against SARS-CoV-2 infection in in vitro assays. One of these drugs, Azelastine an antihistamine currently available as a nasal spray, has been identified as a potential topical preventive or post-exposure anti-COVID-19 approach.CEBINA, in collaboration with Professor Robert Konrat, a renowned structural biologis...

CELL AND GENE THERAPY

Dyadic International, Inc. | December 23, 2021

Dyadic International, Inc. a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve access to biologic vaccines and drugs at flexible commercial scales, announced it is the recipient of one of thirty-two project grants awarded by the National Institute for Innovation in Manufacturing Biopharmaceuticals funded through the White House’s American Rescue ...

INDUSTRIAL IMPACT

Inhibrx, Inc. | March 04, 2022

Inhibrx, Inc. a biotechnology company with four clinical programs in development and a strong emerging pipeline, announced that the U.S. Food and Drug Administration, or FDA, has granted orphan-drug designation for INBRX-101 for the treatment of alpha-1 antitrypsin deficiency, or AATD. "We believe this designation from the FDA acknowledges the significant unmet need for novel therapeutic options in a patient community where the standard of care has not s...

CELL AND GENE THERAPY

Mission Bio | April 20, 2022

Mission Bio, Inc., a leader in high-throughput single-cell DNA and multi-omics analysis, announced today a co-marketing agreement with S2 Genomics, Inc., a leading developer of laboratory automation solutions for processing solid tissues for single-cell applications, to provide a single streamlined workflow for solid tumor applications from sample prep to analysis. Christine A. Iacobuzio-Donahue, MD, Ph.D., Director of the Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer ...